Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Dose-Finding Study of Weekly Pemetrexed With Radiotherapy in Locally Advanced Pancreatic Cancer
2007-002936-27Phase 2Terminated
- Sponsor
- Istituto Oncologico Romagnolo
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in pancreatic adenocarcinoma (PDAC), sponsored by Istituto Oncologico Romagnolo. Primary endpoint: Feasibility and safety (maximum tolerated dose of pemetrexed with radiotherapy). Started Nov 2007; status: terminated.
02
Drugs
pemetrexed
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2007-002936-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002936-27.